Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sunil Parikh has a total of 344 co-authors. Here are the top co-authors by number of shared publications:

  • Francesca T. Aweeka

    School of Pharmacy University of California, San Francisco, San Francisco General Hospital San Francisco California USA

    7 shared publications
  • Amy Kristine Bei

    Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA

    6 shared publications
  • Fangyong Li

    Yale Center for Analytical Sciences, Yale School of Public Health , New Haven, Connecticut

    6 shared publications
  • Martina Wade

    Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA

    6 shared publications
  • Liusheng Huang

    Department of Clinical Pharmacy, University of California-San Francisco, San Francisco General Hospital , San Francisco, California , USA

    5 shared publications
  • Norah Mwebaza

    Infectious Disease Research Collaboration, Kampala, Uganda

    5 shared publications

Latest Publications

  • Open Access

    Identification of genetic variants in Pfs25 and functional evaluation in mosquito infection

    by Alessandra Orfano, Awa Cisse, Yicheng Guo, Leeah Han, Nathan Fikadu, Laty G. Thiam, Aboubacar Ba, Rebecca Li, Mariama N. Pouye, Khadidiatou Mangou, et al.

    Transmission-blocking vaccines (TBVs) are a promising strategy to reduce malaria transmission by targeting parasite stages within the mosquito. However, parasite genetic diversity may limit vaccine efficacy. We used next-generation amplicon deep sequencing to identify non-synonymous single nucleotide polymorphisms (SNPs) in Pfs25 from 184 Plasmodium falciparum isolates from Senegal, Tanzania, Ghana, and Burkina Faso. Prioritized SNPs were introduced into P. falciparum via CRISPR-Cas9. For the G116C variant, gametocyte development was evaluated by microscopy and qPCR, and mosquito infectivity was assessed by SMFAs. We identified 26 SNPs, including 24 novel variants. Functional assays showed that the Pfs25 G116C mutation did not affect gametocyte development or exflagellation. SMFA showed no significant differences in oocyst prevalence or intensity between mutant and WT parasites. These findings highlight the importance of integrating genetic surveillance with functional validation to guide the development of effective transmission blocking interventions.

  • Open Access

    Magnetic Coercivity Signatures of Malaria Hemozoin: Methodology and Validation via 16th-Century Medici Family Remains

    by Mallory D. Cox, Michael Corolla, Valentina Giuffra, Antonio Fornaciari, Gino Fornaciari, Lia Kalinkos, Lillian Rakas Jackson, Joseph Vinetz, Amy K. Bei, Giulia Riccomi, et al.

    Malaria is a parasitic disease caused by the Plasmodium spp. parasite that invades red blood cells and metabolizes hemoglobin to form hemozoin, an iron-rich crystalline by-product. Hemozoin remains in tissues (e.g., bone marrow) and serves as a biomarker for detecting malaria in living individuals and archaeological remains. We investigated the magnetic properties of hemozoin from four Plasmodium species alongside an uninfected bone marrow control to determine if magnetic coercivity can detect hemozoin in bone tissue. We tested our methodology using osteoarchaeological remains from Francesco I de’ Medici (1541-1587) and Cardinal Giovanni de’ Medici (1543-1562), who, according to historical records, died of malaria - later confirmed by biomolecular methods as Plasmodium falciparum. Hemozoin samples from their rib bones exhibit magnetic coercivity values consistent with Plasmodium falciparum. Our approach leverages distinctive magnetic properties of hemozoin to develop a new method for identifying malaria in archaeological remains and to support future malaria detection efforts.

  • Extending the Duration of Artemether-Lumefantrine Treatment for Uncomplicated Plasmodium falciparum Malaria: Updated US Centers for Disease Control and Prevention Guidance Based on Review of Surveillance, Consultations, and Published Data

    by Jimee Hwang, Eric S Halsey, Mateusz M Plucinski, Joel L N Barratt, Julie R Gutman, Michelle A Chang, Seymour G Williams, Kimberly E Mace, Jessica T Lin, Philip J Rosenthal, et al.

    Background: Artemisinin-based combination therapies (ACTs) are recommended for treatment of uncomplicated Plasmodium falciparum malaria; artemether-lumefantrine (AL) is the only ACT available in the United States. Reports of AL treatment failure among international travelers raise concerns about the continued adequacy of the standard 3-day AL regimen for travelers. Methods: We reviewed US malaria surveillance data, clinical consultation records, and antimalarial molecular resistance surveillance data at the Centers for Disease Control and Prevention (CDC). We also conducted a literature review and meta-analysis to assess the risk of treatment failure following treatment with AL or atovaquone-proguanil (AP) in travelers treated in nonendemic settings and reviewed the efficacy and safety of AL regimens with durations longer than the standard 3-day (6-dose) course. Results: From November 2022 through October 2025, CDC was consulted on 47 P. falciparum treatment failures, including 40 following AL-based and 7 following AP-based treatments. All reported travel to Africa, and 62% presented with severe malaria. Among AL failures, 85% were late recrudescences occurring 1–8 weeks after initial treatment. In the meta-analysis, the pooled AL treatment failure risk was higher for data collected in 2018 or later (7% [95% CI, 1%–32%]) compared to before 2018 (4% [95% CI, 2%–8%]), although the difference was not statistically significant (P = .3). Extended AL regimens, particularly a 5-day (10-dose) course, were well tolerated and consistently achieved higher lumefantrine exposure. Conclusions: These findings informed updated CDC guidance recommending an extended 5-day (10-dose) course of AL for treating uncomplicated P. falciparum malaria in the United States.


  • Impact of Dolutegravir‐, Lopinavir/Ritonavir‐, and Efavirenz‐Based Antiretrovirals on Piperaquine Pharmacokinetics in Ugandan Children Living with HIV

    by Richard Kajubi, Malik Koire, Meghan E. Whalen, Francis Orukan, Jaffer Okiring, Florence Marzan, Kacey Richards, Audun J. Lier, Justin Goodwin, McKenzie Colt, et al.

    Dihydroartemisinin–piperaquine is increasingly used for malaria treatment and chemoprevention in children with HIV co‐infection. Its efficacy and safety are associated with piperaquine exposure, which can be compromised by drug–drug interactions with antiretroviral therapy. In a prospective, open‐label study, we evaluated the pharmacokinetics of piperaquine following a 3‐day standard dihydroartemisinin–piperaquine regimen in malaria‐uninfected Ugandan children living with HIV receiving either dolutegravir‐, lopinavir/ritonavir‐, or efavirenz‐based antiretroviral therapies. Children without HIV aged 11–17 and 3–10 years were enrolled as control groups to match (a) the dolutegravir and (b) lopinavir/ritonavir and efavirenz groups, respectively ( n = 30 per group). Intensive pharmacokinetic sampling for piperaquine over 42 days was completed. Compared to controls, overall piperaquine exposure, as measured by area under the concentration–time curve from the 3 rd dihydroartemisinin–piperaquine dose to 42 days in the dolutegravir group was similar but terminal piperaquine concentrations were reduced by 32% on day 28 ( P = 0.02) and 64% on day 42 ( P < 0.0001). In contrast, overall piperaquine exposure in the lopinavir/ritonavir group increased by 240% ( P < 0.0001), with day 42 concentration increasing by 91% ( P < 0.0001), while exposure with efavirenz was reduced by 69% ( P < 0.0001), with day 42 concentration reducing by 92% ( P < 0.0001). Electrocardiographic monitoring during co‐administration with lopinavir/ritonavir identified two transient grade 3 changes that resolved. Efavirenz and lopinavir/ritonavir have opposing effects on piperaquine exposure in children living with HIV, which may impact efficacy and toxicity, respectively, although co‐administration in this study did not yield concerning safety findings. Dolutegravir reduced only terminal concentrations significantly, which may shorten the duration of post‐treatment chemoprophylaxis.

  • Open Access

    Anopheles Mosquitoes Exposed to Long-Acting Antimalarials via Drug-Supplemented Bloodmeal Absorb Drug but Do Not Suffer Fitness Costs

    by Morgan M Goheen, Alessandra Orfanó, Sié Rodrigue Dah, Brian D Foy, Doug E Brackney, Fangyong Li, Jean-Bosco Ouédraogo, Dari F Da, Roch K Dabiré, Anyirekun Fabrice Somé, et al.

    Background: The World Health Organization's recommendations for antimalarial chemoprevention and mass treatment use in endemic areas have greatly expanded, allowing more flexibility in demographic groups and regions targeted. An overlooked aspect of expanding human population-level drug exposure is the downstream impact of a drug on the vector. Anopheles mosquitoes refeed often with ≥ 4 bloodmeals during their lifespan. This provides repeated opportunities for mosquitoes to ingest a drug via bloodmeals taken from people with antimalarials in the bloodstream and raises questions as to the drug’s impact on mosquitoes. Methods: We supplemented bloodmeals with physiologic levels of long-acting antimalarials to assess drug exposure impact on Anopheles mosquito fitness and determine drug absorption extent. Results: We did not observe any significant differences in mosquito feeding, behavior, fecundity, or viability after amodiaquine, desethylamodiaquine, piperaquine, and sulfadoxine-pyrimethamine ingestion in laboratory-reared Anopheles gambiae or field-derived Anopheles coluzzii mosquitoes. Interrogating drug distribution within mosquitoes utilizing liquid chromatography-tandem mass spectrometry, desethylamodiaquine, amodiaquine's longer-acting active metabolite, was fed at half and twice reported Cmax concentrations; the drug was dose-dependently detected in pooled whole mosquitoes, midguts, and hemolymph. This was statistically significant for whole mosquitoes harvested at 24 and 120 hours, and midguts harvested at 24 hours. Between 24 and 120 hours, the drug decreased in midguts but increased in hemolymph. Conclusions: We show sustained biochemical evidence of antimalarial absorption into Anopheles hemolymph following bloodmeal ingestion without fitness costs. These studies provide a foundation to next assess vector-stage antimalarial drug exposure impact on parasite development in infected mosquitoes, which could in turn have implications for transmission dynamics and drug resistance spread.

  • Top Cited Papers

    Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial

    by A Fabrice Somé, Anthony Somé, Emmanuel Sougué, Cheick Oumar W Ouédraogo, Ollo Da, S Rodrigue Dah, Frederic Nikièma, Tereza Magalhaes, Lyndsey I Gray, Will Finical, et al.


  • Open Access

    Two Mosquito Salivary Antigens Demonstrate Promise as Biomarkers of Recent Exposure to Plasmodium falciparum–Infected Mosquito Bites

    by Sarah Lapidus, Morgan M Goheen, Mouhamad Sy, Awa B Deme, Ibrahima Mbaye Ndiaye, Younous Diedhiou, Amadou Moctar Mbaye, Kelly A Hagadorn, Seynabou Diouf Sene, Mariama Nicole Pouye, et al.

    Measuring malaria transmission intensity using the traditional entomological inoculation rate is difficult. Antibody responses to mosquito salivary proteins like SG6 have been used as biomarkers of exposure to Anopheles mosquito bites. Here, we investigate four mosquito salivary proteins as potential biomarkers of human exposure to mosquitoes infected with P. falciparum: mosGILT, SAMSP1, AgSAP, and AgTRIO. We tested population-level human immune responses in longitudinal and cross-sectional plasma from individuals with known P. falciparum infection from low and moderate transmission areas in Senegal using a multiplexed magnetic bead-based assay. AgSAP and AgTRIO were the best indicators of recent exposure to infected mosquitoes. Antibody responses to AgSAP, in a moderate endemic area, and to AgTRIO in both low and moderate endemic areas, were significantly higher than responses in a healthy non-endemic control cohort (p-values = 0.0245, 0.0064, and P. falciparum infection and declined 3 months after infection. Reactivity to AgSAP and AgTRIO peaked after infection, with no differences between transmission seasons within region or between low and moderate transmission regions. This suggests that reactivity reflects exposure to infectious mosquitoes or recent bites rather than general mosquito exposure. Kinetics suggest reactivity is relatively short-lived. AgSAP and AgTRIO are promising candidates to incorporate into multiplexed assays for serosurveillance of population-level changes in P. falciparum-infected mosquito exposure.


  • Open Access

    Noninvasive in vivo photoacoustic detection of malaria with Cytophone in Cameroon

    by Aayire C. Yadem, Jillian N. Armstrong, Mustafa Sarimollaoglu, Civian Kiki Massa, Jean-Michel Ndifo, Yulian A. Menyaev, Anastasie Mbe, Kacey Richards, Martina Wade, Yushun Zeng, et al.

    Current malaria diagnostics are invasive, lack sensitivity, and rapid tests are plagued by deletions in target antigens. Here we introduce the Cytophone, an innovative photoacoustic flow cytometer platform with high-pulse-rate lasers and a focused ultrasound transducer array to noninvasively detect and identify malaria-infected red blood cells (iRBCs) using specific wave shapes, widths, and time delays generated from the absorbance of laser energy by hemozoin, a universal biomarker of malaria infection. In a population of Cameroonian adults with uncomplicated malaria, we assess our device for safety in a cross-sectional cohort (n = 10) and conduct a performance assessment in a longitudinal cohort (n = 20) followed for 30 ± 7 days after clearance of parasitemia. Longitudinal cytophone measurements are compared to point-of-care and molecular assays (n = 94). Cytophone is safe with 90% sensitivity, 69% specificity, and a receiver-operator-curve-area-under-the-curve (ROC-AUC) of 0.84, as compared to microscopy. ROC-AUCs of Cytophone, microscopy, and RDT compared to quantitative PCR are not statistically different from one another. The ability to noninvasively detect iRBCs in the bloodstream is a major advancement which offers the potential to rapidly identify both the large asymptomatic reservoir of infection, as well as diagnose symptomatic cases without the need for a blood sample.


  • Open Access

    Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children

    by Justin Goodwin, Richard Kajubi, Kaicheng Wang, Fangyong Li, Martina Wade, Francis Orukan, Liusheng Huang, Meghan Whalen, Francesca T. Aweeka, Norah Mwebaza, et al.

    Standard diagnostics used in longitudinal antimalarial studies are unable to characterize the complexity of submicroscopic parasite dynamics, particularly in high transmission settings. We use molecular markers and amplicon sequencing to characterize post-treatment stage-specific malaria parasite dynamics during a 42 day randomized trial of 3- versus 5 day artemether-lumefantrine in 303 children with and without HIV (ClinicalTrials.gov number NCT03453840). The prevalence of parasite-derived 18S rRNA is >70% in children throughout follow-up, and the ring-stage marker SBP1 is detectable in over 15% of children on day 14 despite effective treatment. We find that the extended regimen significantly lowers the risk of recurrent ring-stage parasitemia compared to the standard 3 day regimen, and that higher day 7 lumefantrine concentrations decrease the probability of ring-stage parasites in the early post-treatment period. Longitudinal amplicon sequencing reveals remarkably dynamic patterns of multiclonal infections that include new and persistent clones in both the early post-treatment and later time periods. Our data indicate that post-treatment parasite dynamics are highly complex despite efficacious therapy, findings that will inform strategies to optimize regimens in the face of emerging partial artemisinin resistance in Africa.


  • Open Access

    Two mosquito salivary antigens demonstrate promise as biomarkers of recent exposure to P. falciparum infected mosquito bites

    by Sarah Lapidus, Morgan M. Goheen, Mouhamad Sy, Awa B. Deme, Ibrahima Mbaye Ndiaye, Younous Diedhiou, Amadou Moctar Mbaye, Kelly A. Hagadorn, Seynabou Diouf Sene, Mariama Nicole Pouye, et al.

    Background: Measuring malaria transmission intensity using the traditional entomological inoculation rate is difficult. Antibody responses to mosquito salivary proteins such as SG6 have previously been used as biomarkers of exposure to Anopheles mosquito bites. Here, we investigate four mosquito salivary proteins as potential biomarkers of human exposure to mosquitoes infected with P. falciparum : mosGILT, SAMSP1, AgSAP, and AgTRIO. Methods: We tested population-level human immune responses in longitudinal and cross-sectional plasma samples from individuals with known P. falciparum infection from low and moderate transmission areas in Senegal using a multiplexed magnetic bead-based assay. Results: AgSAP and AgTRIO were the best indicators of recent exposure to infected mosquitoes. Antibody responses to AgSAP, in a moderate endemic area, and to AgTRIO in both low and moderate endemic areas, were significantly higher than responses in a healthy non-endemic control cohort (p-values = 0.0245, 0.0064, and P. falciparum infection and declined 3 months after infection. Discussion: Reactivity to both AgSAP and AgTRIO peaked after infection and did not differ seasonally nor between areas of low and moderate transmission, suggesting reactivity is likely reflective of exposure to infectious mosquitos or recent biting rather than general mosquito exposure. Kinetics suggest reactivity is relatively short-lived. AgSAP and AgTRIO are promising candidates to incorporate into multiplexed assays for serosurveillance of population-level changes in P. falciparum -infected mosquito exposure.